Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly
PR90791
SINGAPORE, July 22, 2021 /PRNewswire=KYODO JBN/ --
- Acquisition of Cialis(R) in the People's Republic of China to bolster
Menarini's Men's Health portfolio and drive multichannel coverage
-This is a significant milestone for Menarini Asia operations as it
commemorates its 10th anniversary of being established in 13 major healthcare
markets in Asia-Pacific
A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the
world's largest Italian biopharmaceutical company, announced today the
completion of its acquisition of Cialis(R) in the People's Republic of China
from Eli Lilly and Company. Through the acquisition, Menarini will take over
ownership of the brand and assume all sales, marketing and distribution
responsibilities.
Cialis(R) was first approved by the European Medicines Agency in 2002 followed
by the U.S. Food and Drug Administration ("FDA") in 2003 and then NMPA
(National Medical Products Administration) in 2005, as well as in more than 120
other countries.
With Cialis(R), Menarini intends to strategically expand its nationwide
coverage across the Retail, E-Commerce and Hospital channels and deliver on its
growth ambition in the second-largest healthcare market worldwide. Besides
Men's Health, Menarini is focused on major therapeutic categories including
Dermatology, Allergy/Respiratory, Cardiovascular, Gastroenterology, Pain
Management, Consumer Healthcare, Oncology and Anti-Infectives.
Maurizio Luongo, Chief Executive Officer, Menarini Asia-Pacific said, "The
acquisition of Cialis(R) is a testament to Menarini's commitment to invest and
grow our well diversified Primary and Speciality Care portfolio in the
Asia-Pacific region, which is an increasingly important engine of growth for
the Group. We are excited to take the brand from strength to strength in China
with our well proven, multi-pronged go-to-market strategy for our Men's Health
portfolio in China. We look forward to harnessing the combined strengths of the
complementary products in this portfolio to invigorate lives and relationships
across the nation."
About Cialis(R)(Tadalafil)
Cialis is indicated in China for the treatment of men with erectile dysfunction
(ED), and men with both ED and the signs and symptoms of benign prostatic
hyperplasia.
Cialis is not for women or children.
It is important to note that Cialis is not to be taken with medicines called
"nitrates" such as nitroglycerin, as tadalafil may potentiate the hypotensive
effect of nitrates; and also GC stimulator, such as riociguat. PDE5 inhibitors,
including tadalafil may potentiate the hypotensive effects of GC stimulators;
or if allergic to Cialis or Adcirca (tadalafil), or any of its ingredients.
About Menarini Asia-Pacific
Menarini Asia-Pacific is a member of the Menarini Group, with a heritage of
over 130 years and over 17,000 employees in more than 140 countries. Here in
Asia-Pacific, Menarini's vision is to be a leading provider of important
healthcare brands to improve the lives of people in the region. Menarini
Asia-Pacific operates across the entire commercial value chain, from clinical
development, regulatory approval and product launch to lifecycle management
with a diverse portfolio of proprietary and partnered brands in key therapeutic
fields, including Consumer Health, Dermatology, Allergy/Respiratory,
Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care
and Men's Health. For the Financial Year 2020, the Menarini Group clocked sales
revenues of US 4.6 billion dollars, of which the Asia Pacific region has grown
to become a dynamic engine of growth for the Group with more than 10% revenue
contribution.
For more information about Menarini Asia-Pacific, please visit:
www.menariniapac.com
SOURCE Menarini Asia-Pacific
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。